ATE329268T1 - Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen - Google Patents

Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen

Info

Publication number
ATE329268T1
ATE329268T1 AT01981868T AT01981868T ATE329268T1 AT E329268 T1 ATE329268 T1 AT E329268T1 AT 01981868 T AT01981868 T AT 01981868T AT 01981868 T AT01981868 T AT 01981868T AT E329268 T1 ATE329268 T1 AT E329268T1
Authority
AT
Austria
Prior art keywords
vitamin
compounds
determining
initial dose
dose
Prior art date
Application number
AT01981868T
Other languages
English (en)
Inventor
Michael J Amdahl
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE329268T1 publication Critical patent/ATE329268T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01981868T 2000-10-13 2001-10-12 Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen ATE329268T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24012600P 2000-10-13 2000-10-13

Publications (1)

Publication Number Publication Date
ATE329268T1 true ATE329268T1 (de) 2006-06-15

Family

ID=22905214

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01981868T ATE329268T1 (de) 2000-10-13 2001-10-12 Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen

Country Status (12)

Country Link
US (1) US20030092686A1 (de)
EP (1) EP1334367B1 (de)
JP (1) JP2004532801A (de)
AT (1) ATE329268T1 (de)
AU (2) AU1348302A (de)
CA (1) CA2423316A1 (de)
CY (1) CY1106146T1 (de)
DE (1) DE60120458T2 (de)
DK (1) DK1334367T3 (de)
ES (1) ES2266276T3 (de)
PT (1) PT1334367E (de)
WO (1) WO2002031514A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015246A1 (en) * 2000-06-27 2010-01-21 Shire International Licensing B.V. Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6066091A (en) * 1998-02-23 2000-05-23 North Carolina State University Methods, systems and products for determining drug withdrawal intervals

Also Published As

Publication number Publication date
US20030092686A1 (en) 2003-05-15
EP1334367B1 (de) 2006-06-07
JP2004532801A (ja) 2004-10-28
WO2002031514A3 (en) 2003-06-05
WO2002031514A2 (en) 2002-04-18
EP1334367A2 (de) 2003-08-13
DE60120458D1 (de) 2006-07-20
CA2423316A1 (en) 2002-04-18
AU2002213483B2 (en) 2007-03-29
PT1334367E (pt) 2006-10-31
AU1348302A (en) 2002-04-22
ES2266276T3 (es) 2007-03-01
DE60120458T2 (de) 2007-01-11
DK1334367T3 (da) 2006-10-09
CY1106146T1 (el) 2011-06-08

Similar Documents

Publication Publication Date Title
WO2001027119A3 (de) Substanzbibliothek enthaltend bicyclische imidazo-5-yl-amine und/oder bicyclische imidazo-3-yl-amine
ATE218327T1 (de) Verfahren zur herstellung einer pharmazeutischen formulierung
EE200000318A (et) Uudsed ühendid
ATE321048T1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und - tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
ATE502648T1 (de) Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
DE69832209D1 (de) Verfahren zur Herstellung von 3,3-Dimethylbutyraldehyd durch Oxidation von 3,3-Dimethylbutanol
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
PT73879B (de) 1-carboxyalkanoylindolin-2-carbonsauren verfahren zu ihrer herstellung und pharmazeutische praeparate enthaltend diese verbindungen sowie ihre therapeutische verwendung
DE69904922D1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
DE69802918D1 (de) Vwf propeptide enthaltendes pharmazeutisches präparat
ATE268749T1 (de) Verfahren zur herstellung von iopamidol
DE69824839D1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5-halogen-pyridinen, verwendbar als cox-2 inhibitoren
RU92004530A (ru) Производные гуанидиналкил-1,1-бис-фосфоновой кислоты, способ их получения, лекарственные средства и способ их получения
ATE238315T1 (de) Verfahren zur herstellung von dinatriumpamidronat
DE60120458D1 (de) Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen
DK0752991T3 (da) Indeno[1,2-e]pyrazin-4-oner, fremstilling af disse forbindelser og lægemidler indeholdende disse forbindelser
DK0614366T3 (da) Anvendelse af creatinphosphat eller phosphoenolpyrodruesyre til behandling af tumorer
ATE111734T1 (de) Verfahren zur herstellung von direktkomprimierten, cephalosporansäure derivate enthaltendentabletten.
DE69820580D1 (de) Verfahren zur Abtrennung von Metallen durch micellare Ultrafiltration, geeignet zur Behandlung von radioaktiven Abfallstoffen
IS1801B (is) Pýridýlbisfosfónöt til notkunar sem efni til lækninga
DE58904328D1 (de) Verfahren zur desinfektion von medizinischen abformmassen.
DE59300386D1 (de) Verfahren zur Herstellung von Siliciumnitrid, Ausgangsverbindung hierfür sowie Verfahren zu dessen Herstellung.
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1334367

Country of ref document: EP

REN Ceased due to non-payment of the annual fee